8-K: TuHURA Biosciences Completes Strategic Acquisition of Kineta, Expanding Immuno-Oncology Pipeline with Phase 2 Ready Asset

TuHURA Biosciences, Inc. has successfully completed its acquisition of Kineta, Inc., integrating a Phase 2 ready VISTA inhibiting monoclonal antibody, TBS-2025, into its immuno-oncology pipeline and unlocking a new tranche of PIPE financing.

Summary

• TuHURA Biosciences, Inc. completed the previously announced acquisition of Kineta, Inc. on June 30, 2025, pursuant to the Merger Agreement dated December 11, 2024, and amended May 5, 2025.
• Each share of Kineta common stock was converted into the right to receive 0.185298 shares of TuHURA common stock, resulting in an aggregate issuance of approximately 2,868,169 shares of TuHURA Common Stock at closing.
• Kineta shareholders are also entitled to their pro rata portion of approximately 1,129,885 additional shares of TuHURA Common Stock to be issued after six months following the closing, subject to adjustment for losses incurred or accrued during that period.
• Kineta shareholders will also receive their pro rata share of cash consideration from disposed asset payments related to legacy Kineta assets, if any, at a later date.
• In lieu of fractional shares of TuHURA Common Stock, a cash payment equal to the product of the fractional share and $5.7528 will be made.
• The acquisition adds TBS-2025 (formerly KVA12123), a novel VISTA inhibiting monoclonal antibody, to TuHURA's immuno-oncology pipeline, which is Phase 2 ready.
• The completion of the acquisition unlocks the fourth tranche of funds from a $12.5 million aggregate PIPE financing that was announced on June 3, 2025.

Sentiment

Score: 8

Explanation: The document announces the successful completion of a strategic acquisition that significantly expands the company's pipeline with a Phase 2 ready asset and unlocks a tranche of financing, indicating positive progress and future potential in addressing critical unmet medical needs in oncology.

Positives

• The acquisition adds TBS-2025, a Phase 2 ready novel VISTA inhibiting monoclonal antibody, to TuHURA's late-stage immuno-oncology pipeline.
• TBS-2025 has the potential to overcome acquired resistance to cancer immunotherapy, complementing TuHURA's existing IFx-2.0 program which targets primary resistance.
• The acquisition provides synergies across TuHURA's therapeutic focus and its antibody drug conjugate (ADC) technology.
• TBS-2025 can be administered as an intact monoclonal antibody alone or in combination with other therapeutics, and is being investigated for conjugation to a Delta Opioid Receptor inhibitor(s) for a potential bi-functional, bi-specific ADC.
• The completion of the acquisition unlocks the fourth tranche of funds from a $12.5 million aggregate PIPE financing.
• TBS-2025 was well tolerated in a dose escalation Phase 1/2 trial at doses up to 1,000mg, both as monotherapy (n=24) and in combination with pembrolizumab (n=16).
• Pharmacokinetic and pharmacodynamic data for TBS-2025 demonstrated greater than 90% receptor occupancy across the every two-week dosing interval.

Risks

• Forward-looking statements are not guarantees of future performance, and actual results or developments may differ materially from those set forth in these statements.
• Factors that could cause actual results to differ materially are described in detail in the company's registration statements, reports, and other filings with the SEC.
• The aggregate number of additional shares of TuHURA Common Stock to be issued after six months following the closing is subject to adjustment for losses incurred or accrued during that six-month period.
• Cash consideration received by Kineta pursuant to disposed asset payments related to legacy Kineta assets, if any, will be made at a later date and is not guaranteed.

Future Outlook

TuHURA plans to initiate a Phase 2 randomized trial involving the VISTA inhibiting antibody (TBS-2025) in the second half of 2025. The company is currently planning to investigate TBS-2025 in combination with a menin inhibitor in NPM1 mutated AML, aiming to augment response rates and decrease relapse rates in patients with relapsed or refractory AML. Additionally, TuHURA is investigating the possibility of conjugating TBS-2025 to a Delta Opioid Receptor inhibitor(s) to create a potential immunomodulatory, bi-functional, and bi-specific ADC targeting myeloid derived suppressor cells (MDSCs) in the tumor microenvironment.

Management Comments

• "While TuHURA’s IFx-2.0 is being investigated for its potential to overcome primary resistance to checkpoint inhibitors in Merkel cell carcinoma, the acquisition of VISTA expands TuHURA’s pipeline with a Phase 2 ready drug candidate, TBS-2025, which TuHURA believes has the potential to overcome acquired resistance to cancer immunotherapy." James Bianco, M.D., President and Chief Executive Officer of TuHURA.
• "The acquisition provides for synergies across both TuHURA’s therapeutic focus as well as with TuHURA’s antibody drug conjugate (ADC) technology." James Bianco, M.D.
• "Not only can TBS-2025 be administered as the intact mAb alone or in combination with other therapeutics, we are also investigating the possibility of it being conjugated to a Delta Opioid Receptor inhibitor(s) resulting in a potential immunomodulatory, bi-functional, and bi-specific ADC targeting myeloid derived suppressor cells (MDSCs) in the tumor microenvironment (TME)." James Bianco, M.D.
• "We believe, in a relatively inexpensive, small Phase 2 study, we can determine if TBS-2025, our VISTA inhibiting antibody, can augment the response rates seen with menin inhibitors and decrease the rate of relapse in patients with NMP1 mutated relapsed or refractory AML where menin inhibitors are the current standard of care." James Bianco, M.D.

Industry Context

The acquisition positions TuHURA to address both primary and acquired resistance to cancer immunotherapy, a significant challenge in oncology. By integrating a VISTA inhibitor, TuHURA is targeting a distinct immune checkpoint predominantly expressed on myeloid cells, offering a novel approach to overcome immunosuppression in the tumor microenvironment. This expands their competitive landscape beyond their existing IFx-2.0 program. The focus on Acute Myeloid Leukemia (AML) and the potential for Antibody Drug Conjugate (ADC) technology integration align with current trends in precision oncology and combination therapies, aiming to improve treatment outcomes in difficult-to-treat cancers.

Comparison to Industry Standards

• TBS-2025 (formerly KVA12123) was investigated in a dose escalation Phase 1/2 trial, both as monotherapy and in combination with pembrolizumab, in patients with relapsed and/or treatment-refractory advanced solid tumors.
• TBS-2025 was well tolerated at doses up to 1,000mg in both the monotherapy arm (n=24) and the pembrolizumab combination therapy arm (n=16), indicating a favorable safety profile consistent with expectations for a therapeutic antibody.
• Pharmacokinetic and pharmacodynamic data for TBS-2025 demonstrated greater than 90% receptor occupancy across the every two-week dosing interval, which is a strong indicator of sustained target engagement and potential efficacy.
• The planned Phase 2 study in NPM1 mutated AML with a menin inhibitor aims to augment response rates and decrease relapse rates, addressing a high unmet need in a specific AML patient population where menin inhibitors are the current standard of care, suggesting a targeted and potentially impactful clinical strategy.
• VISTA is an immune checkpoint distinct from more commonly targeted checkpoints like PD-1/PD-L1, as it is predominately expressed on myeloid cells and quiescent T cells, offering a differentiated mechanism of action to address immunosuppression in the tumor microenvironment.

Stakeholder Impact

• Shareholders (TuHURA): Benefit from pipeline expansion with a Phase 2 ready asset, potential for future growth, and the unlocking of a tranche of PIPE financing.
• Shareholders (Kineta): Receive TuHURA common stock at closing, with entitlement to additional shares and potential cash consideration from legacy assets, completing the merger transaction.
• Patients: Potential for new therapeutic options for cancer, particularly those with acquired resistance to immunotherapy or specific mutations like NPM1 in AML, through the advancement of TBS-2025.
• Employees: Implied integration of Kineta's operations and personnel into TuHURA, though specific details are not provided.

Next Steps

• TuHURA plans to initiate a Phase 2 randomized trial involving the VISTA inhibiting antibody (TBS-2025) in the second half of 2025.
• TuHURA is investigating the possibility of conjugating TBS-2025 to a Delta Opioid Receptor inhibitor(s) for a potential immunomodulatory, bi-functional, and bi-specific ADC.
• Financial statements of businesses acquired and pro forma financial statements will be filed by amendment to the Current Report on Form 8-K no later than 71 days after June 30, 2025.
• Cash consideration from disposed legacy Kineta assets, if any, will be made to Kineta shareholders at a later date in accordance with the merger agreement.
• An aggregate of approximately 1,129,885 additional shares of TuHURA Common Stock will be issued to Kineta shareholders after six months following the closing, subject to adjustment.

Key Dates

Recommendation

Keywords

TuHURA Biosciences, Kineta, acquisition, merger, immuno-oncology, VISTA inhibitor, monoclonal antibody, TBS-2025, KVA12123, cancer immunotherapy, Phase 2 trial, AML, NPM1 mutated, MDSCs, PIPE financing, HURA, biotechnology, pharmaceutical